Literature DB >> 22230401

2B4 (CD244) is involved in eosinophil adhesion and chemotaxis, and its surface expression is increased in allergic rhinitis after challenge.

A E El-Shazly1, M Henket, P P Lefebvre, R Louis.   

Abstract

A role for the subtypes of CD2 Ig superfamily receptors has been recently demonstrated in eosinophilic inflammation in experimental asthma and atopic asthmatics. We investigated the functions of 2B4 (CD244) molecules in eosinophil adhesion and chemotaxis, and correlated the results to the pathophysiology of allergic rhinitis (AR). Herein, we show that agonistic stimulation of 2B4 by C1.7, the anti-human 2B4 functional grade purified antibody, resulted in significant increase of eosinophils and eosinophil cell line (Eol-1 cells) adhesion to collagen type IV, and random migration. These functions were associated with tyrosine kinase phosphorylation of several protein residues of low molecular weight. Flow cytometry (FACS) experiments demonstrated that Eol-1 cells, normal peripheral blood eosinophils and eosinophils from AR patients, express surface 2B4 molecules. In vitro AR model demonstrated that the CC-chemokine receptor CCR3 stimulation by eotaxin induced significant increase in the expression of surface 2B4 in eosinophils and Eol-1 cells. Immunofluorescence confocal microscopy images showed that eotaxin induces also redistribution of 2B4 molecules towards the pseudopods in eosinophils and Eol-1 cells, changing their shape. Blocking of 2B4 molecules by the corresponding neutralizing antibody inhibited eotaxin induced Eol-1-adhesion, chemotaxis and the cytoskeleton changes. Pretreatment of Eol-1 cells with 1 microM genistein blocked eotaxin-induced Eol-1 adhesion, chemotaxis and 2B4 up-regulated expression. In vivo correlation demonstrated the expression of 2B4 molecules in eosinophils from AR patients to be significantly increased, after nasal provocation challenge. These results identify a novel role for 2B4 molecules in eosinophil functional migratory response and may point to a novel tyrosine kinase-mediated ligation between CCR3 receptor and 2B4 co-receptor in eosinophil chemotaxis. If so, then 2B4 molecules would be a novel target for therapeutic modalities in diseases characterized by eosinophilia such as AR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22230401     DOI: 10.1177/039463201102400413

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  6 in total

Review 1.  Human eosinophils and mast cells: Birds of a feather flock together.

Authors:  Piper A Robida; Pier Giorgio Puzzovio; Hadas Pahima; Francesca Levi-Schaffer; Bruce S Bochner
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

2.  Novel association between vasoactive intestinal peptide and CRTH2 receptor in recruiting eosinophils: a possible biochemical mechanism for allergic eosinophilic inflammation of the airways.

Authors:  Amr E El-Shazly; Dominique Y Begon; Gaelle Kustermans; Mohammad Arafa; Estelle Dortu; Monique Henket; Philippe P Lefebvre; Renaud Louis; Philippe Delvenne
Journal:  J Biol Chem       Date:  2012-11-20       Impact factor: 5.157

3.  Complex 2B4 regulation of mast cells and eosinophils in murine allergic inflammation.

Authors:  Moran Elishmereni; Nanna Fyhrquist; Roopesh Singh Gangwar; Sari Lehtimäki; Harri Alenius; Francesca Levi-Schaffer
Journal:  J Invest Dermatol       Date:  2014-07-07       Impact factor: 8.551

Review 4.  Advances in Understanding the Roles of CD244 (SLAMF4) in Immune Regulation and Associated Diseases.

Authors:  Lin Sun; Xiaokun Gang; Zhuo Li; Xue Zhao; Tong Zhou; Siwen Zhang; Guixia Wang
Journal:  Front Immunol       Date:  2021-03-24       Impact factor: 7.561

5.  Clinical features and prognosis according to genomic mutations in primary and metastatic lesions of non-small-cell lung cancer.

Authors:  Wei Zhang; Wenjuan Han; Bo Yu; Xin Zhao; Gaojun Lu; Wendy Wu; Yi Zhang
Journal:  Thorac Cancer       Date:  2022-04-24       Impact factor: 3.223

6.  Eosinophils in fungus-associated allergic pulmonary disease.

Authors:  Sumit Ghosh; Scott A Hoselton; Glenn P Dorsam; Jane M Schuh
Journal:  Front Pharmacol       Date:  2013-02-01       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.